相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes
D. Serra et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2011)
Unraveling the Science of Incretin Biology
Michael A. Nauck
AMERICAN JOURNAL OF MEDICINE (2009)
Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin
G. Bolli et al.
DIABETES OBESITY & METABOLISM (2009)
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2009)
Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2009)
Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus
E. Bosi et al.
DIABETES OBESITY & METABOLISM (2009)
Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus
Masatoshi Kikuchi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Absorption, Metabolism, and Excretion of [14C]Vildagliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, in Humans
Handan He et al.
DRUG METABOLISM AND DISPOSITION (2009)
Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes
Bo Ahren et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
Michael Boschmann et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Treatment with the Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves Fasting Islet-Cell Function in Subjects with Type 2 Diabetes
David A. D'Alessio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Pharmacokinetics and Pharmacodynamics of Vildagliptin in Healthy Chinese Volunteers
Pei Hu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes
David M. Nathan et al.
DIABETES CARE (2009)
Rosiglitazone no longer recommended
[Anonymous]
LANCET (2008)
Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance
P. Augstein et al.
DIABETES OBESITY & METABOLISM (2008)
Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia
W. A. Scherbaum et al.
DIABETES OBESITY & METABOLISM (2008)
Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited
B. F. Burkey et al.
DIABETES OBESITY & METABOLISM (2008)
Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2008)
Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial
C. Pan et al.
DIABETIC MEDICINE (2008)
Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus
V. Fonseca et al.
HORMONE AND METABOLIC RESEARCH (2008)
Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naive Patients with Type 2 Diabetes: Comparison with Metformin
B. Goeke et al.
HORMONE AND METABOLIC RESEARCH (2008)
Effect of Vildagliptin on Glucagon Concentration During Meals in Patients with Type 1 Diabetes
J. E. Foley et al.
HORMONE AND METABOLIC RESEARCH (2008)
Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia
Andrea Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes
Koichiro Azuma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose
Kristina M. Utzschneider et al.
DIABETES CARE (2008)
Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance
Julio Rosenstock et al.
DIABETES CARE (2008)
Management of type 2 diabetes in treatment-naive elderly patients
Richard E. Pratley et al.
DIABETES CARE (2007)
Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects
Surya P. Ayalasomayajula et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion
Andrea El-Ouaghlidi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Dose proportionality and the effect of food on vildagliptin, a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers
Gangadhar Sunkara et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug-naive patients with Type 2 diabetes
A. Schweizer et al.
DIABETIC MEDICINE (2007)
Evaluation of pharmacokinetic interactions between vildagliptin and digoxin in healthy volunteers
Yon-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin
Y.-L. He et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
V. Fonseca et al.
DIABETOLOGIA (2007)
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects
Yan-Ling He et al.
CURRENT MEDICAL RESEARCH AND OPINION (2007)
Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT
Yan-Ling He et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes
F. Xavier Pi-Sunyer et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2007)
The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients
Bogdan Balas et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study
A. J. Garber et al.
DIABETES OBESITY & METABOLISM (2007)
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2007)
Vildagliptin in drug-naive patients with type 2 diabetes: A 24-week, double-blind, randomized, placebo-controlled, multiple-dose study
S. Dejager et al.
HORMONE AND METABOLIC RESEARCH (2007)
Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes - A 24-week, double-blind, randomized trial
Julio Rosenstock et al.
DIABETES CARE (2007)
Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin
Emanuele Bosi et al.
DIABETES CARE (2007)
Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus
Yan-Ling He et al.
CLINICAL PHARMACOKINETICS (2007)
The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase-IV inhibitor, vildagliptin, in healthy volunteers
Yan-Ling He et al.
CLINICAL PHARMACOKINETICS (2007)
Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
N. Matikainen et al.
DIABETOLOGIA (2006)
Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
R. E. Pratley et al.
HORMONE AND METABOLIC RESEARCH (2006)
Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats
BF Burkey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response
S Ristic et al.
DIABETES OBESITY & METABOLISM (2005)
Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes - Potential importance of selectivity over dipeptidyl peptidases 8 and 9
GR Lankas et al.
DIABETES (2005)
Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β-cell function in patients with type 2 diabetes
A Mari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Improved meal-related β-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year
B Ahrén et al.
DIABETES CARE (2005)
Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by vildagliptin ((2S)-{[3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2-carbonitrile)
I Brandt et al.
BIOCHEMICAL PHARMACOLOGY (2005)
Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes
HJ Mest et al.
DIABETOLOGIA (2005)
Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes
B Ahrén et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes
B Ahrén et al.
DIABETES CARE (2004)
Characterization of GLP-1 effects on β-cell function after meal ingestion in humans
B Ahrén et al.
DIABETES CARE (2003)
1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine:: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
EB Villhauer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Dipeptidyl peptidase IV inhibitor treatment stimulates β-cell survival and islet neogenesis in streptozotocin-induced diabetic rats
JA Pospisilik et al.
DIABETES (2003)
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion
PE MacDonald et al.
DIABETES (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
分享论文
